What weight loss on tirzepatide actually looks like, week by week

Step 1, the starter phase: why 2.5 mg is a settling-in period, not a holding pattern

Treatment begins at 2.5 mg once weekly. The first pen's job is to let your body adjust to the medicine, not to drive the majority of weight change. Most people notice modest appetite reduction in this phase, but the bigger shifts come later. Nausea and digestive discomfort, if they appear, are most common here and tend to ease within a couple of weeks.

A practical tip that patients often find useful: keeping your pen in the fridge door (visible alongside the milk) builds the habit of a consistent weekly schedule. Consistent dosing days matter; erratic timing makes it harder to build the routine that sustains long-term results. Any questions about when or how to administer your doses belong with your prescriber and the Patient Information Leaflet in your pack.

After roughly four weeks, a prescriber reviews whether titration to 5 mg is appropriate. Dose increases continue in this pattern (each step roughly a month apart) up to the highest dose you tolerate well. You can read more about the full process on how long Mounjaro takes to work.

Step 2, the active weight-loss phase: what the SURMOUNT-1 data show

The SURMOUNT-1 trial followed 2,539 adults with obesity over 72 weeks. At the 15 mg maintenance dose, average weight reduction was around 20–21%, and in some analyses, closer to 22.5%. That translates to roughly 22 kg for someone starting at 110 kg. The 10 mg group averaged around 19.5%, and 5 mg around 15%.

These figures come from the SURMOUNT-1 trial, published in the New England Journal of Medicine, which is the primary evidence base NICE used when evaluating tirzepatide. For a detailed breakdown of the numbers by dose and timepoint, the tirzepatide weight-loss results page covers them in full. The most important caveat: trial participants followed structured diet and activity programmes alongside the medicine. Lifestyle changes are part of the mechanism, not optional extras.

Progress in this phase is rarely linear. Most people lose weight more quickly in months one to four, then see the rate slow as they approach a new set point. That deceleration is normal physiology, not a sign something has gone wrong.

Step 3, the plateau and beyond: what happens when the rate of loss slows

A slower rate of change after six months is expected. The body responds to sustained energy deficit by adapting its metabolism, an effect that isn't unique to tirzepatide and has been observed across weight-management research for decades. The question is whether weight is still trending downward, even gently, or whether it has genuinely stalled.

If you feel your progress has stopped, it's worth reviewing with your prescriber before drawing conclusions. There are clinical reasons weight loss can stall: a dose that could still be increased, a change in eating patterns that offset the medicine's effect, or a medical factor that warrants investigation. The page on what to do if you're not losing weight on tirzepatide covers the common causes and what can be done.

NICE guidance notes that if a patient loses less than 5% of body weight after six months at the highest tolerated dose, continuing treatment should be reviewed clinically, NICE Technology Appraisal TA1026 sets this out in its recommendations. That review is a clinical conversation, not an automatic stop.

For context on how long treatment typically continues, the guidance on duration of tirzepatide treatment is a useful reference point, and questions about cost for a longer course are covered on the Mounjaro pricing and access page.

Who tends to see the strongest results with tirzepatide?

Starting BMI matters in absolute terms: someone beginning at BMI 40 has more weight to lose than someone at BMI 28, so percentage-based comparisons can be misleading. What the data consistently show is that the highest tolerated dose correlates with the greatest average outcome, which is why slow, supported titration matters rather than rushing to a higher dose before tolerance is established.

Adherence to the weekly schedule, engagement with dietary changes, and adequate protein intake to preserve muscle mass all shape the outcome. Tirzepatide reduces appetite markedly in many people; that's useful for controlling intake but requires some attention to nutritional quality rather than simply eating less of everything. If you're thinking about starting treatment, our overview of weight-loss treatments sets out the landscape, and the average weight loss on tirzepatide page looks at realistic expectations in more depth.

A prescriber who knows your full medical picture is the right person to judge whether this medicine is likely to suit you. Our clinical team at nume reviews every consultation personally. If you're ready to take the first step, start your free consultation and a GPhC-registered prescriber will review your case the same day.